[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100324002":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":18,"locations":28,"responsibleParty":42,"collaborators":18,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":18,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":18,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":18,"overallStatus":63,"whyStopped":18,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Mahidol University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","A single dose of Tdap vaccine at GA 27 - 36 weeks",[13],"Biological: Tdap vaccine",{"label":15,"type":16,"description":17,"interventionNames":18},"Active comparator","NO_INTERVENTION","dT vaccine as standard protocol",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":18},"BIOLOGICAL","Tdap vaccine",[9],[25],{"name":26,"affiliation":5,"role":27},"Nalat Sompagdee, MD","PRINCIPAL_INVESTIGATOR",[29],{"facility":30,"status":18,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":18},"Nalat Sompagdee","Bangkok Noi","Bangkok","10700","Thailand","TH",{"type":37,"coordinates":38},"Point",[39,40],100.47798,13.76266,{"lat":40,"lon":39},{"type":27,"investigatorFullName":30,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Principal Investigator","100324002","early-phase-1-seroprevalence-of-bordetella-pertussis-antibodies-and-anti-pertussis-antibody-response-after-a-single-dose-of-tdap-in-pregnant-thai-women-100324002",true,"NCT03498300","Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women","Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Tdap) in Pregnant Thai Women","Inclusion Criteria:\n\n* Thai pregnant women age at least 18 years\n* No known underlying disease\n* Singleton pregnancy without maternal or fetal complications\n* Gestational age not more than 20 weeks at the time of recruitment\n* Desired for delivery at Siriraj Hospital\n\nExclusion Criteria:\n\n* Pregnant women who have any contraindication to Tdap vaccine including\n\n  1. History of serious allergic reaction to any components of Tdap vaccine\n  2. History of seizure or coma after receiving Tdap vaccine in childhood\n  3. Having an underlying disease involving central nervous system (e.g., epilepsy, Guillain-Barré syndrome)\n* History of serious reactions after receiving Tdap vaccine (e.g., severe pain, severe swelling at the injection site)\n* Recently had Tdap vaccine injection\n* Denied for Tdap vaccine injection","FEMALE","18 Years",{"count":54,"type":55},129,"ACTUAL","INTERVENTIONAL",[58],"EARLY_PHASE1","This study evaluated the seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.\n\nAll seronegative participants received Tdap, while seropositive participants were equally randomized into 2 groups. Half of seropositive participants received Tdap and the other half received tetanus-diphtheria (Td) as standard protocol.",[61,62],"Pertussis","Pregnancy Related","COMPLETED","2020-03-11",{"date":66,"type":55},"2020-03-24",{"date":68,"type":55},"2018-05-09",{"date":70,"type":55},"2019-04-13",{"name":5,"class":6},1]